Champions Oncology (CSBR) ticker CSBR Financial Results Summary

# Champions Oncology (CSBR) Q1 2026 Financial Results Summary

Hackensack, NJ – September 15, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025.

### First Quarter and Recent Highlights:
– **Total Revenue:** $14.0 million, a slight decrease of **0.7%** compared to $14.1 million for the same quarter last year.
– **Adjusted EBITDA:** $60,000, down from $2.0 million year-over-year.
– **New Leadership:** Rob Brainin appointed as Chief Executive Officer.
– **Sequential Growth:** Solid sequential growth meeting expectations.

### Financial Performance Overview:
– **Oncology Revenue Breakdown:**
– **Total Oncology Revenue:** $14.0 million vs. $14.1 million for the same period last year.
– Service revenue experienced a decline of **3%**, falling by **$400,000**.
– Data license revenue increased by **$300,000**.

– **Operating Costs:**
– **Total Costs and Operating Expenses:** Rose to $14.5 million, an increase of **14.1%** compared to $12.7 million in the same quarter last year.

– **Loss from Operations:**
– Reported a loss of $527,000, compared to a gain of $1.3 million in the first quarter of fiscal 2025.
– Included costs: $208,000 in stock-based compensation and $358,000 in depreciation and amortization.

– **Adjusted EBITDA Calculation:**
– Adjusted EBITDA was $60,000 for Q1 FY 2026 vs. $2.0 million for Q1 FY 2025.

– **Cost of Revenue:**
– **Cost of Oncology Revenue:** Increased to $8.0 million, a rise of **13.1%** from $7.1 million year-over-year.

– **Gross Margin:**
– Gross margin for the quarter was **43%**, down from **50%** in the prior year.

### Detailed Expense Analysis:
– **Research and Development Expenses:**
– Increased by **43.2%**, totaling $2.1 million, up from $1.5 million in the prior year due to greater investment in sequencing and data licensing platform development.

– **Sales and Marketing Expenses:**
– Increased by **10.5%**, reaching $1.9 million compared to $1.7 million last year.

– **General and Administrative Expenses:**
– Increased by **1.7%**, totaling $2.6 million compared to $2.5 million last year.

### Cash Flow and Financial Position:
– **Operating Activities:** Net cash provided by operating activities was approximately $600,000, supported by receivables conversion.
– **Investing Activities:** Net cash used was approximately $46,000 for lab and computer equipment.
– **Financing Activities:** Used approximately $14,000 due to financing lease payments, slightly offset by proceeds from options exercises.

– **Cash Position:** Ended the quarter with approximately $10.3 million in cash and no debt.

### Dividends and Share Repurchase:
– The company did not declare any quarterly dividend or any share repurchase during this quarter.

### Financial Outlook:
– Champions Oncology anticipates continued topline revenue growth and margin improvement from a robust services pipeline and increased demand for proprietary data offerings.

### Conclusion:
Champions Oncology has begun fiscal year 2026 with steady revenue, despite a slight year-over-year decrease in total revenue and adjusted EBITDA. The appointment of Rob Brainin as CEO marks a pivotal moment for the company as it aims to leverage its existing strengths and enhance future growth prospects.

Full details of the Company’s financial results will be available in the Company’s Form 10-Q at www.championsoncology.com.

—